Empagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer cardiovascular benefits in diabetes.
• The role of SGLT2 inhibitors in the acute post-myocardial infarction (MI) setting remains uncertain.
• This study investigates empagliflozin's effect on left ventricular ejection fraction (LVEF) recovery and major adverse cardiac events (MACE) in ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI).

Purpose of the Study:

• To evaluate the association of empagliflozin with LVEF recovery in STEMI patients after PCI.
• To assess the impact of empagliflozin on MACE in this patient population.
• To explore potential benefits of SGLT2 inhibition in the acute phase of myocardial infarction.

Main Methods:

• A single-center, double-blind, randomized, placebo-controlled trial.
• 117 patients with STEMI undergoing PCI were randomized to receive empagliflozin 10 mg or placebo daily for 40 days.
• Primary endpoint: change in LVEF from baseline to day 40. Secondary endpoint: MACE (cardiovascular death, MI, stroke).

Main Results:

• Empagliflozin significantly increased LVEF recovery at day 40 (mean increase: 7.35% vs. 2.96%; P = 0.000272).
• The LVEF improvement remained significant after covariate adjustment (adjusted difference: 3.44%; P = 0.003).
• MACE did not differ significantly between groups (3.8% vs. 7.5%; P = 0.68); adverse events were comparable and rare.

Conclusions:

• Empagliflozin demonstrated a significant improvement in LVEF recovery in STEMI patients post-PCI.
• The observed LVEF improvement is a promising early prognostic signal, though MACE was not significantly reduced.
• Larger multicenter trials are needed to confirm clinical benefits and generalize findings to broader STEMI populations.